The effort led by St. Jude Children's Research Hospital scientists identified the gene as a potential marker of relapse risk and involved the most comprehensive search yet for genomic changes in relapsed childhood acute lymphoblastic leukemia
MEMPHIS, Tenn., March 9, 2011 /PRNewswire-USNewswire/ -- Despite dramatically improved survival rates for childhood acute lymphoblastic leukemia (ALL), relapse remains a leading cause of death from the disease. Work led by St. Jude Children's Research Hospital investigators identified mutations in a gene named CREBBP that may help the cancer resist steroid treatment and fuel ALL's return.
CREBBP plays an important role in normal blood cell development, helping to switch other genes on and off. In this study, researchers found that 18.3 percent of the 71 relapsed-ALL patients carried alterations in the DNA sequence of CREBBP. In contrast, the gene's sequence was changed in just one of the 270 young leukemia patients whose cancer did not return.
Investigators say the gene is a potential indicator of relapse risk because of the high frequency of CREBBP mutations in relapsed patients and evidence the changes persisted from diagnosis or emerged at relapse from subpopulations of leukemia cells present from the beginning. Researchers also found evidence the changes occur in important regulatory regions of the gene and affect cell function, including how cancer cells respond to the steroids that play an important role in cancer treatment. The work appears in the March 10 issue of the scientific journal Nature.
"This study gives us further evidence that detailed genomic studies can identify important mutations that influence tumor response to treatment," said Charles Mullighan, M.D., Ph.D., assistant member of the St. Jude Department of Pathology. Mullighan and Jinghui Zhang, Ph.D., an associate member of the St. Jude Department of Computational Biology, are co-first authors. Mullighan is also the corresponding and senior author.
In the same issue of Nature, investigators also reported that deletions and deactivating mutations in CREBBP and a related gene known as EP300 occurred in about one-third of patients identified with one of the two most common subtypes of B-cell non-Hodgkin lymphoma. Mullighan is one of that study's five St. Jude co-authors.
Previous reports have linked deletions or chromosome rearrangements involving CREBBP to rare cases of acute leukemia. But this is the first study linking changes in the gene's DNA sequence to leukemia and lymphoma, cancers of the blood and bone marrow.
ALL is the most common childhood cancer. While ALL cure rates have climbed to 90 percent, the disease is often deadly if it returns. This study was designed to advance understanding of the biological basis of treatment failure. "The results of this study emphasize that there are additional genetic changes that help determine whether a child does well or relapses," Mullighan said.
The findings stem from the largest DNA sequencing project yet for ALL, which is diagnosed in about 3,000 U.S. children annually. Researchers from St. Jude and the National Cancer Institute tracked changes in 300 genes from 23 young ALL patients. For each gene, researchers compared the DNA makeup in the patient's normal cells with the sequence at diagnosis and relapse.
The effort turned up 52 non-inherited mutations in 32 genes, many for the first time. The group included four in CREBBP. When researchers checked another 341 young leukemia patients for alteration in CREBBP, they found that 13 of the 71 relapsed-ALL patients carried changes. In two more, pieces of CREBBP's DNA were deleted.
"The robust and accurate analytical method that we developed for processing such a large data volume made discovery of the CREBBP mutations possible," Zhang said. "This exciting finding illustrates that genomic sequencing can provide insight into not only disease initiation, but progression and prognosis as well."
Fourteen mutations were found scattered throughout CREBBP. The list includes an alteration also linked to Rubinstein-Taybi syndrome, a rare inherited multisystem developmental disorder, as well as mutations linked to the cell's steroid response. Four alterations occurred in the region of the gene that regulates DNA expression through a process of chemical modification known as acetylation. Working in mouse cells growing in the laboratory, researchers showed that CREBBP mutations disrupted acetylation of key DNA targets.
When researchers treated CREBBP-mutated leukemia cells growing in the laboratory with the steroid dexamethasone, a majority showed resistance to the drug. The study included cells from nine ALL subtypes. But researchers found most of the cells proved sensitive to another drug. That drug, vorinostat, uses a different mechanism to impact acetylation. Researchers now plan to test vorinostat in a mouse model of relapsed ALL.
The other authors of this paper are Lawryn Kasper, Stephanie Lerach, Debbie Payne-Turner, Sue Heatley, Linda Holmfeldt, J. Racquel Collins-Underwood, Jing Ma, Ching-Hon Pui, Sharyn Baker, Paul Brindle and James Downing, all of St. Jude; Letha Phillips, formerly of St. Jude, and Kenneth Buetow, NCI Center for Bioinformatics and NCI Laboratory of Population Genetics.
The work was supported in part by supported in part by a National Cancer Institute Cancer Center Support Grant and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other catastrophic diseases. Ranked the No. 1 pediatric cancer hospital by Parents magazine and the No. 1 children's cancer hospital by U.S. News & World Report, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude has treated children from all 50 states and from around the world, serving as a trusted resource for physicians and researchers. St. Jude has developed research protocols that helped push overall survival rates for childhood cancer from less than 20 percent when the hospital opened to almost 80 percent today. St. Jude is the national coordinating center for the Pediatric Brain Tumor Consortium and the Childhood Cancer Survivor Study. In addition to pediatric cancer research, St. Jude is also a leader in sickle cell disease research and is a globally prominent research center for influenza.
Founded in 1962 by the late entertainer Danny Thomas, St. Jude freely shares its discoveries with scientific and medical communities around the world, publishing more research articles than any other pediatric cancer research center in the United States. St. Jude treats more than 5,700 patients each year and is the only pediatric cancer research center where families never pay for treatment not covered by insurance. St. Jude is financially supported by thousands of individual donors, organizations and corporations without which the hospital's work would not be possible. For more information, go to www.stjude.org.
SOURCE St. Jude Children's Research Hospital